Purple Biotech Ltd. (PPBT)
PPBT Stock Price Chart
Explore Purple Biotech Ltd. interactive price chart. Choose custom timeframes to analyze PPBT price movements and trends.
PPBT Company Profile
Discover essential business fundamentals and corporate details for Purple Biotech Ltd. (PPBT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Nov 2015
Employees
9.00
Website
https://purple-biotech.comCEO
Gil Efron
Description
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
PPBT Financial Timeline
Browse a chronological timeline of Purple Biotech Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.98.
Earnings released on 15 May 2026
EPS came in at -$0.09 surpassing the estimated -$3.80 by +97.63%.
Earnings released on 13 Mar 2026
EPS came in at -$19.85 falling short of the estimated -$3.40 by -483.82%.
Stock split effective on 2 Mar 2026
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2025
EPS came in at -$0.29 falling short of the estimated -$0.26 by -11.54%.
Earnings released on 6 Aug 2025
EPS came in at -$0.40 falling short of the estimated -$0.21 by -90.48%.
Earnings released on 21 May 2025
EPS came in at -$0.17 .
Earnings released on 10 Mar 2025
EPS came in at -$0.26 falling short of the estimated -$0.22 by -18.18%.
Earnings released on 15 Nov 2024
EPS came in at -$1.37 falling short of the estimated -$1.20 by -14.17%.
Stock split effective on 17 Sept 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 16 Aug 2024
EPS came in at -$1.60 falling short of the estimated -$0.16 by -900.00%.
Earnings released on 21 May 2024
EPS came in at -$3.00 matching the estimated -$3.00.
Earnings released on 5 Mar 2024
EPS came in at -$6.40 falling short of the estimated -$3.40 by -88.24%.
Earnings released on 21 Nov 2023
EPS came in at -$4.20 surpassing the estimated -$4.40 by +4.55%.
Earnings released on 22 Aug 2023
EPS came in at -$4.60 surpassing the estimated -$5.00 by +8.00%.
Earnings released on 16 May 2023
EPS came in at -$4.20 surpassing the estimated -$7.00 by +40.00%.
Earnings released on 8 Feb 2023
EPS came in at -$6.00 matching the estimated -$6.00.
Earnings released on 8 Nov 2022
EPS came in at -$0.27 falling short of the estimated -$0.21 by -28.57%.
Earnings released on 4 Aug 2022
EPS came in at -$39.33 .
Earnings released on 12 May 2022
EPS came in at -$81.93 .
Earnings released on 9 Feb 2022
EPS came in at -$18.19k .
Earnings released on 30 Sept 2021
EPS came in at -$35.83 .
Earnings released on 5 Aug 2021
EPS came in at -$41.39 falling short of the estimated -$0.01 by -413.81k%.
PPBT Stock Performance
Access detailed PPBT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
